Raza Ali, Sood Gagan K
Ali Raza, Department of Internal Medicine, St. Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX 77030, United States.
World J Gastroenterol. 2014 Apr 21;20(15):4115-27. doi: 10.3748/wjg.v20.i15.4115.
Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Multiple treatment options are available for HCC including curative resection, liver transplantation, radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agent like sorafenib. The treatment of HCC depends on the tumor stage, patient performance status and liver function reserve and requires a multidisciplinary approach. In the past few years with significant advances in surgical treatments and locoregional therapies, the short-term survival of HCC has improved but the recurrent disease remains a big problem. The pathogenesis of HCC is a multistep and complex process, wherein angiogenesis plays an important role. For patients with advanced disease, sorafenib is the only approved therapy, but novel systemic molecular targeted agents and their combinations are emerging. This article provides an overview of treatment of early and advanced stage HCC based on our extensive review of relevant literature.
肝细胞癌（HCC）是全球第五大常见肿瘤。HCC有多种治疗选择，包括根治性切除、肝移植、射频消融、经动脉化疗栓塞、放射性栓塞以及索拉非尼等全身性靶向药物。HCC的治疗取决于肿瘤分期、患者的体能状态和肝功能储备，需要多学科方法。在过去几年中，随着手术治疗和局部区域治疗的显著进展，HCC的短期生存率有所提高，但疾病复发仍然是一个大问题。HCC的发病机制是一个多步骤的复杂过程，其中血管生成起着重要作用。对于晚期疾病患者，索拉非尼是唯一获批的治疗方法，但新型全身性分子靶向药物及其联合用药正在不断涌现。本文在广泛回顾相关文献的基础上，对早期和晚期HCC的治疗进行综述。
